Ninčević, V.; Omanović Kolarić, T.; Roguljić, H.; Kizivat, T.; Smolić, M.; Bilić Ćurčić, I.
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Int. J. Mol. Sci. 2019, 20, 5831.
https://doi.org/10.3390/ijms20235831
AMA Style
Ninčević V, Omanović Kolarić T, Roguljić H, Kizivat T, Smolić M, Bilić Ćurčić I.
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. International Journal of Molecular Sciences. 2019; 20(23):5831.
https://doi.org/10.3390/ijms20235831
Chicago/Turabian Style
Ninčević, Vjera, Tea Omanović Kolarić, Hrvoje Roguljić, Tomislav Kizivat, Martina Smolić, and Ines Bilić Ćurčić.
2019. "Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes" International Journal of Molecular Sciences 20, no. 23: 5831.
https://doi.org/10.3390/ijms20235831
APA Style
Ninčević, V., Omanović Kolarić, T., Roguljić, H., Kizivat, T., Smolić, M., & Bilić Ćurčić, I.
(2019). Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. International Journal of Molecular Sciences, 20(23), 5831.
https://doi.org/10.3390/ijms20235831